Atea Pharmaceuticals, Inc. (AVIR) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 28.12M USD | Liabilities, Current |
| Cash and equivalents | 76.55M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 142.92M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $28.12M | $76.55M | $142.92M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $33.37M | $79.32M | $176.69M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $39.78M | $95.71M | $206.12M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $20.18M | $77.34M | $251.97M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $20.12M | $87.72M | $291.99M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $21.75M | $119.39M | $306.04M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $18.60M | $64.70M | $390.02M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $25.19M | $98.46M | $384.35M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $26.62M | $243.39M | $258.82M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $41.31M | $160.91M | $380.58M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $32.38M | $143.82M | $434.28M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $18.89M | $137.89M | $457.24M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $16.16M | $213.70M | $394.36M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $12.36M | $183.25M | $437.23M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $18.48M | $188.46M | $458.25M | (m) | (m) | (m) |
| 2022-09-30 | $669.49M | $15.63M | $176.41M | $488.56M | $4.51M | (m) | 42.82× |
| 2022-06-30 | (m) | $25.11M | $684.48M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $28.61M | $705.54M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $56.88M | $764.38M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $262.05M | $839.66M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $273.65M | $816.46M | (m) | $50.00M | (m) | (m) |
| 2021-03-31 | (m) | $254.28M | $833.75M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $315.80M | $850.12M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $10.82M | $105.38M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $115.79M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $17.15M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $2.44M | $21.66M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | $25.60M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $34.49M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |